Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: the EORTC 1608 STEAM trial

Zotiraciclib (TG02) is an oral multi-cyclin dependent kinase (CDK) inhibitor thought to inhibit tumor growth via CDK-9-dependent depletion of survival proteins such as c-MYC and MCL-1 which are frequently overexpressed in glioblastoma.

Source: European Journal of Cancer - December 18, 2023 Category: Cancer & Oncology Authors: Emilie Le Rhun, Thierry Gorlia, J örg Felsberg, Joost Jongen, Claude-Alain Maurage, François Ducray, Dorothee Gramatzki, Peter Hau, Olivier L. Chinot, Matthias Preusser, Stephanie Cartalat, Patrick Roth, Martin van den Bent, Julia Furtner, Maike Collien Tags: Clinical Trial Source Type: research